Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 54

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 54
---
ifungal       
 prophylaxis for these diseases can be reviewed in (i) Fishman et al Clinical Transplantation. 2019;33:e13587, (ii) Hematopoietic           
 Cell Transplantation (cancernetwork.com), (iii) Cooper et al Journal of the National Comprehensive Cancer Network 2016;14:882-913          
 and (iv) Los Arcos et al Infection (2021) 49:215–231.                                                                                      |

| 18 | Aguilar-Guisado                                                                
 et al Clin Transplant 2011;25:E629–38; Mace et al MMWR 202;70:1–35.            |
| 19 | Queener                                                                        
 et al JID 1997;165:764-768; Dow and Smith New Microb New Infect 2022;45:100964 |

| 20 | https://www.ecdc.europa.eu/en/dengue-monthly#:~:text=This%20is%20an%20increase%20of%2032%20653%20cases% 
 20and%2032,853%20deaths%20have%20been%20reported.                                                       |

| 21 | https://www.cdc.gov/rsv/php/surveillance/index.html#cdc_survey_profile_surveys_used-rsv-burden-estimates.                            |
| 22 | In 2014, we signed a cooperative                                                                                                     
 research and development agreement with the United States Army Medical and Materiel Development Activity (Agreement W81XWH-14-0313). 
 Under this agreement, we agreed to submit an NDA for Tafenoquine to the FDA (as Arakoda), while the US Army agreed to finance the    
 bulk of the necessary development activities in support of that goal.                                                                |

| 23 | Zottig et al Military Medicine 
 2020; 185 (S1): 687.           |

<div align='center'>4</div>

The FDA and Australia’s medicinal regulatory agency, the Therapeutic Goods Administration, subsequently approved Arakoda (brand name in the U.S.) and Kodatef (brand name in Australia), respectively, for prevention of malaria in travelers in 2018. Prescribing information and guidance for patients can be found at www.arakoda.com. The features and benefits of Tafenoquine for malaria prophylaxis, some of which have been noted by third-party